27.6 C
New York
Wednesday, June 3, 2026

Tag: manufacturing capabilities

newssourceFORcompanyinformationcontent1marketreleases

Persist AI Teams up with Microsize and Micromacinazione (Micmac) to Launch First-of-Its-Kind Early-Stage “Micromill” Formulation Platform, Enabling Drug Development Decision With Milligrams of API

New collaboration delivers a fully integrated formulation workflow from early solubility studies to high-throughput dissolution, stability, and in-process analytics, making drug formulation less artisanal...

Ampace Redefines UPS Battery Role in AI Data Centers at Datacloud Global Congress 2026

CANNES, France, June 2, 2026 /PRNewswire/ -- Ampace is exhibiting at Datacloud Global Congress 2026 (Booth 301, Palais -1 Hall, Cannes) this week, presenting...

Home Control International Limited (Stock Code: 1747.HK) Announces 2025 Interim Results

Net Profit Increased by 56.9% Year-on-year to US$5.0 million Strategic Pursuit of Growth: Venturing into the Home Healthcare Sector Financial Highlights For the six months ended 30...

Workhorse Group and Motiv Electric Trucks Executed Definitive Agreement to Combine, Creating a Leading Medium-Duty Electric Truck OEM in North America

Joins Workhorse’s proven vehicles, manufacturing capabilities and national dealer network with Motiv’s diverse product portfolio and top fleet relationships

T1 Energy and Corning Deal Accelerates ‘Made in America’ Solar Momentum

T1 Energy and Corning Deal Boosts U.S. solar supply chain, advances towards domestic solar modules.

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and CEO.

On Demand Pharmaceuticals Welcomes HHS Leadership to Showcase Breakthrough Domestic Pharmaceutical Manufacturing Capabilities

ROCKVILLE, Md., Aug. 14, 2025 /PRNewswire/ -- Today, On Demand Pharmaceuticals (ODP) hosted senior officials from the U.S. Department of Health and Human Services...

Vivos Holdings Completes Combination with Nice-Pak

Transaction closing clears the way for the combined organization to focus on collaboration and growth opportunities across a range of hygiene and personal care...

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update.

Global Axial Flux Motor Market Growth at 66.7% CAGR – Revolutionizing Electric Mobility & Industry | Valuates Reports

What is the Market Size of Axial Flux Motor Market? BANGALORE, India, Aug. 13, 2025 /PRNewswire/ -- The global market for Axial Flux Motor was...

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S.Expansion is part of AbbVie's previously announced commitment...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsManufacturing capabilities

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers